This application is for a new (type 1) PHS Institutional National Research Service Award to prepare fellows for an academic career in Hematology at the University of California, Los Angeles. The proposal is for 3 fellowship slots in the first year and 4 thereafter to support research programs in years 2 and 3 of a fellowship in Hematology/Oncology. Support is not requested for the first year's clinical experience, which provides extensive training through inpatient and outpatient Hematology and Oncology services at the Clinical Health Sciences Center of UCLA and at affiliated hospitals at the Wadsworth VA and at the Los Angeles Orthopaedic Hospital. After completion of the first (clinical) year, the trainee will begin his or her research experience in the chosen field and with the appropriate faculty mentor. The faculty consists of 21 scientists, about equally divided into 3 research foci, namely, hematopoiesis and stem cell biology, lymphocytes and host defense and hemostasis/thrombosis and vascular biology, each research focus of which is directed by a specialist in that field. All of the mentors have peer-reviewed Federal funding (20 of 21 with NIH grants), demonstrated success in training doctoral and/or post-doctoral research fellows, and experience in collaborative translational projects. Highest priority for acceptance of fellows into the program will be given to those whose goals are towards attainment of a PhD degree as part of the Department of Medicine Specialty Training and Advanced Research (STAR) Program, to those who already have dual MD/PhD) degrees, and to fellows with express interest in academic careers and experience in laboratory-oriented research. Strong efforts will be made to recruit fellows from underrepresented minority groups, especially through functional interactions with Drew University of Medicine and Science and the Martin Luther King Hospital in Los Angeles. Research seminars, work-in-progress sessions, and scientific retreats will afford special opportunities for selection of future mentors by fellows and for scientific interchange and project development. The program offers and independently supports additional research training beyond year 3 for those trainees who desire further experience to make the transition to academic investigator. A core curriculum includes required attendance in the """"""""Clinical Research Course"""""""", which covers subjects on research design and analysis, ethics, regulatory issues, grant preparation and responsible conduct of research. The progress of fellows towards completion of their work will be monitored by regular and formal evaluations by the Steering Committee, which includes 4 PhD's among the 6 members, in concert with each fellow's mentor. The training of academic hematologists with expertise in basic, clinical and translational research is an important priority for academic medical centers and this application seeks support for the pivotal 2-year period between clinical training and an eventual career in academic hematology.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Institutional National Research Service Award (T32)
Project #
5T32HL066992-02
Application #
6622639
Study Section
Special Emphasis Panel (ZHL1-CSR-M (F1))
Program Officer
Mondoro, Traci
Project Start
2002-07-01
Project End
2007-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
2
Fiscal Year
2003
Total Cost
$212,734
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Nikanjam, Mina; Capparelli, Edmund V; Lancet, Jeffrey E et al. (2018) Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment. Cancer Chemother Pharmacol 81:171-178
Nikanjam, Mina; Sun, Aida; Albers, Mark et al. (2018) Vincristine-associated Neuropathy With Antifungal Usage: A Kaiser Northern California Experience. J Pediatr Hematol Oncol 40:e273-e277
Sasine, Joshua P; Yeo, Kelly T; Chute, John P (2017) Concise Review: Paracrine Functions of Vascular Niche Cells in Regulating Hematopoietic Stem Cell Fate. Stem Cells Transl Med 6:482-489
Seet, Christopher S; He, Chongbin; Bethune, Michael T et al. (2017) Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids. Nat Methods 14:521-530
Larson, Sarah M; Truscott, Laurel C; Chiou, Tzu-Ting et al. (2017) Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy. Hum Vaccin Immunother 13:1094-1104
Nikanjam, Mina; Patel, Harsh; Kurzrock, Razelle (2017) Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology 6:e1338997
Nikanjam, Mina; Liu, Sariah; Yang, Jincheng et al. (2017) Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. Oncologist 22:576-584
Sasine, Joshua P; Schiller, Gary J (2016) Acute Myeloid Leukemia: How Do We Measure Success? Curr Hematol Malig Rep 11:528-536
Nikanjam, Mina; Liu, Sariah; Kurzrock, Razelle (2016) Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer 139:2135-41
Sasine, Joshua P; Yeo, Kelly T; Chute, John P (2016) Concise Review: Paracrine Functions of Vascular Niche Cells in Regulating Hematopoietic Stem Cell Fate. Stem Cells Transl Med :

Showing the most recent 10 out of 26 publications